Cellectis stem cells today announces the release of a new and improved user friendly format of stem cell derived cardiomyocytes
Published on
Gothenburg, Sweden, September 24th, 2012 – Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies, today announces the release of a new, flexible, and user friendly format of stem cell derived cardiomyocyte product, hES-CMC™.
Gothenburg, Sweden, September 24th, 2012 – Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies, today announces the release of a new, flexible, and user friendly format of stem cell derived cardiomyocyte product, hES-CMC™.
The hES-CMCTM are highly representative of human cardiomyocytes and demonstrate a long life span with maintained functionality, making them the ideal platform for various in vitro applications including drug discovery and toxicity testing.
« Due to their high relevance in various industrial applications the hES-CMC™ represent a really promising system for research and development », said Mathieu Simon, CEO of Cellectis stem cells. « The pharmaceutical industry has a great need for more clinically relevant models early in the drug development process to better predict cardiovascular risk and find new drug targets. We are excited to be able to provide these cells in a convenient format to our customers and partners. »
« In a short time, this is yet another confirmation of the Cellectis’ strategy to become the global market leader for stem cell based in vitro models and related technologies. We have considerably accelerated our developments in this field » said André Choulika, Chairman and CEO of Cellectis Group.